42 results about "Thyroxine measurement" patented technology

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

Thyroxine medications which include combinations of levothyroxine, and / or liothronine, or dextrothyroxine, or thyroid, and one or more iodine salts, or iodine donor compounds are described, which produce a stable thyroxine medication, with a long shelf life. A method for manufacturing the medications is also described.

The present invention relates to compositions comprising thyroxine (T4) and triiodothyronine (T3). More specifically, the invention relates to thyroxine (T4) and triiodothyronine (T3) compositions that include a peptide carrier and thyroxine (T4) and triiodothyronine (T3) covalently attached to at least one of the N-terminus, the C-terminus, a side chain of the peptide carrier, and / or interspersed within the peptide chain; methods for protecting and administering thyroxine (T4) and triiodothyronine (T3); and methods for treating thyroid disorders.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations thereof.

The invention belongs to the technical field of immunodiagnosis, and discloses a thyroxine (T4) enzymatic chemiluminescence quantitative determination kit. The kit disclosed by the invention consists of a T4 standard product, an antibody pre-coated reaction plate, a horseradish peroxidase marker, diluent, cleaning mixture, and chemiluminescence substrate liquid. The kit disclosed by the invention has the advantages of quickness, handiness, sensitiveness, cheapness and high repeatability, and is an important index for diagnosis and therapeutic evaluation of hyperthyroidism and hypothyroidism. The invention has high clinic use value. The invention also provides a method to prepare the kit.

The invention relates to the field of in vitro diagnosis, and in particular to preserving fluid for a micromolecule antigen and an alkaline phosphatase labeled conjugate, and a preparation method thereof. According to the preserving fluid for the micromolecule antigen and the alkaline phosphatase labeled conjugate, the solvent of the preserving fluid is water, and counted by the volume of the preserving fluid, the preserving fluid comprises the following components: 0.2-0.05mol / L of buffer salt, 3-30g / L of protein substance, 0.1-0.4mol / L of saline ions, 5-50g / L of carbohydrate, 0.5-5g / L of surfactant, 50-270g / L of stabilizer and 0.5-5 g / L of preservative; and the pH of the preserving fluid is 7.0-8.0. The activity of thyroxine (T4), triiodothyronine (T3) and the alkaline phosphatase labeled conjugate in the preserving fluid after storage at 37 DEG C for 7 days can be effectively stabilized.

Transthyretin (TTR), a tetrameric thyroxine (T4) carrier protein, is associated with a variety of amyloid diseases. Derivative of biphenyl ethers (BPE), which are shown to interact with a high affinity to its T4 binding site thereby preventing its aggregation and fibrillogenesis. They prevent fibrillogenesis by stabilizing the tetrameric ground state of transthyretin. Two compounds (2-(5-mercapto-[1,3,4]oxadiazol-2-yl)-phenol and 2,3,6-trichloro-N-(4H-[1,2,4]triazol-3-yl) exhibit the ability to arrest TTR amyloidosis. The dissociation constants for the binding of BPEs and compound 11 and 12 to TTR correlate with their efficacies of inhibiting amyloidosis. They also have the ability to inhibit the elongation of intermediate fibrils as well as show nearly complete (>90%) disruption of the preformed fibrils. Biphenyl ethers and compounds 11 and 12 as very potent inhibitors of TTR fibrillization and inducible cytotoxicity.

The invention provides a serum-free culture medium used for full-suspension culture of MDCK (Madin Darby Canine Kidney) cells. The culture medium is prepared from a DMEM / F12 culture medium containing 5g / L of NaCl and the following components: sodium stannite, recombinant human epidermal growth factors, hydrocortisone, recombinant full-chain insulin, prostaglandin E1, human transferrin, thyroxine (T3), vitamin E, cholesterol, ethanol amine, beta-mercaptoethanol, Tween-80, Hypep1510, recombinant human serum albumin ACF and mannitol. With the adoption of the culture medium provided by the invention, the full-suspension culture of the MDCK cells can be carried out very well under the condition that serum is not added; after the MDCK cells are continuously cultured for 20 generations, the average proliferation concentration of the MDCK cells is 2.308*10<6> / mL, the average cell viability is 97.4 percent and the average doubling time is 34.48 hours, so that the serum-free culture medium provides technical supports for developing influenza vaccines of cell matrixes of mammals in China.

The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD- L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.

A mufti-organ gene profiling analysis of the results of an administration to a subject of salmon calcitonin or a parathyroid hormone analogue provides biomarkers of calcitonin treatment efficacy and parathyroid hormone or parathyroid hormone analogue treatment efficacy. Among the biomarkers are the expression profiles of the genes for Y-box binding protein, BMPs, FGFs, IGFs, VEGF, &x3B1;-2-HS glycoprotein (AHSG), OSF, nuclear receptors (steroid / thyroid family) and others. The results obtained support the anabolic effect of salmon calcitonin on bone metabolism.

The invention relates to a thyroxine nanometer magnetic particle chemiluminiscence determinstion kit as well as a preparation method and a detection method thereof. The kit comprises solution containing fluorescein marked thyroxine antibody, suspension of magnetic particles coated with fluorescein antibody, and solution containing alkaline phosphatase marked thyroxine antigen. The kit, the preparation method and the detection method can implement quantitative detection for the thyroxine with lower cost and higher accuracy and precision.

A means for conveniently and accurately measuring thyroxine or thyronine present in the blood or the like is provided: a compound represented by general formula (I) below:wherein L represents a linear or branched-chain linker having 5 to 50 total atoms; X represents one or more thyroxines, thyronines, or residues of derivatives thereof, bound to the main chain and / or side chain of the linker represented by L, a conjugate in the form of the above compound bonded to an avidin protein, and an aqueous dispersion including a microparticles the surface of which is modified with the above conjugate.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin-1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine (T3), Thyroxine (T4), Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth / differentiation factor 15, and Proprotein convertase subtilisin / kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

The invention provides methods for simultaneously detecting or simultaneously quantifying any combination of thyroxine (T4), triiodothyronine (T3), 3,3′-diiodo-L-thyronine (3,3′-T2), 3-iodothyronamine (T1AM), and, optionally, reverse T3 (rT3) in a sample obtained from a human. The method involves a simple, sensitive, accurate, and specific isotope dilution tandem mass spectrometry method for the simultaneous quantification of any combination of T4, T3, 3,3′-T2, T1AM, and, optionally, rT3 in a sample obtained from a human, e.g., in human plasma or serum samples. This assay is far more sensitive than previously described assays for thyronamines and allows quantitation of T1AM in human plasma or serum, including from healthy controls.

The invention discloses an immediate type ophthalmic gelatin of thyroxine liothyronine and a preparation method thereof. 100 milliliters of the immediate type ophthalmic gelatin of thyroxine liothyronine contains 0.1 to 3 grams of thyroxine powder extract, 0.05 to 1 gram of preservative, 1.0 to 7.5 grams of permeation pressure conditioning agent and 30 to 150 grams of gelatin substrate. Remaining components are acid-base buffer regent and water for rejection. The invention enriches the dosage forms of the thyroxine powder extract by optimizing auxiliary materials and improving technology so that lag time in eyes is greatly prolonged and curative effect is improved without adverse stimulus reaction.

The invention provides pharmaceutical compositions for improving the bone loss of hyperthyroid high-conversion type and the reduction of the biomechanical properties of the bone, and relates to an extract of a Chinese medicinal Danshen, or the formula and the production process of pharmaceutical compositions for improving the bone loss of high-conversion type and the reduction of the biomechanicalproperties of the bone caused by the hypersplenism of the thyroid, which is prepared from the following components in parts by weight: 0.1 to 0.3 g of a danshensu and 5 g of crystalline fructose, thepharmaceutical compositions are characterized by being prepared into an injection. The invention further discloses a formula and production process of the injection, a granule and a non-alcoholic beverage. The high-dose thyroxine-induced hyperthyroid high-conversion bone loss animal model proves that the pharmaceutical composition prepared from the danshensu and the fructose can influence the bone metabolism of the rat, promote the bone formation, inhibit the bone resorption, increase the bone mass, improve the bone mineral density and the bone mineral salt content, and improve the performance of the bone biomechanics, and has a good preventive effect on the damage of the bone biological biomechanical properties of the hyperthyroid osteoporosis.

The subject invention provides novel methods and materials for treating diabetic retinopathy. One embodiment of the subject invention involves the co-administration of a somatostatin, or analogue thereof, and a thryoid-related substance such as thyroxine. Somatostatin or thyroid-related substance can be administered in combination, or separately through the same or different modes of administration.

The invention discloses a novel thyroxine hapten luminescent marker and a synthetic method thereof, wherein the synthetic method of the novel thyroxine hapten luminescent marker comprises the steps: A) preparing a trifluoroacetamide compound 2 crude product; B) preparing a trifluoroacetamide compound 3; C) preparing a trifluoroacetamide compound 4; D) preparing a thyroxine methyl ester compound 5; E) preparing a thyroxine methyl ester compound 6; F) preparing a thyroxine methyl ester compound 7; and G) preparing the target product acridine marked novel thyroxine methyl ester. The invention provides the novel compound for chemiluminescence detection of thyroxine and the synthetic route and method thereof; the small-molecular marker is easy to purify, can achieve industrialized production, and improves the detection sensitivity. The defects that protein macromolecular compounds used in conventional detection reagents are expensive and allow differences to be easily produced in the production process are solved.

The invention discloses a method for establishing a rat animal model with hypothyroid cardiac insufficiency. The method comprises the following steps: A, diluting 131I with normal saline to prepare a mixed liquid; B, carrying out intraperitoneal injection on a rat with the mixed liquid; C, detecting at the end of four weeks and the end of eight weeks of the experiment to establish a model. According to the method, the thyroid iodine concentrating capability is understood through radioisotope scanning, and the levels of total triiodothyronine, total thyroxine and thyrotropin in serum are detected to evaluate the thyroid function, and the cardiac ultrasonography and brain natriuretic peptide of the rat are detected to evaluate the heart function. Detection data verifies that the intraperitoneal injection 131I caused rat animal model with hypothyroid cardiac insufficiency is successfully modeled.

Modulation of neural activity in the superior laryngeal nerve (SLN) or cervical sympathetic trunk (CST) is effective in treating diseases and conditions mediated by thyroid and parathyroid hormones, in particular diseases associated with calcitonin secretion (e.g. osteoporosis) or diseases associated with thyroxine secretion (e.g. hypothyroid syndrome).

The present invention discloses a virtual screening method of human transthyretin (hTTR) disturbing chemicals, belonging to the field of methods of screening environmental endocrine disturbing chemicals. According to the virtual screening process, firstly, chemicals are classified based on ten radical groups, then a disturbing effect of each chemical on the hTTR is predicted by using a quantitative structure-active relationship model, so that whether the chemical has a capability of disturbing transport of the thyroxine by the hTTR is determined according to a predicted effect value, and the strength of the disturbing capability is also determined. The process of screening the hTTR disturbing chemicals is simple and reasonable, and the method is accurate and reliable, is easy to be programmed, and can be applied to virtual screening of potential hTTR disturbing chemicals in an application domain and priority setting of potential disturbing chemicals.

The invention discloses a TT7 kit based on a micro-fluidic chip for detecting total thyroxine and preparation and detection methods. The preparation method of the kit comprises the following steps: (1) coating the micro-fluidic chip; (2) marking fluorescent microspheres; (3) assembling the micro-fluidic chip; (4) preparing a calibrated product; and (5) obtaining the total thyroxine TT4 kit based on the micro-fluidic chip. The prepared total thyroxine TT4 kit is determined by adopting a competition law. By selecting a highly sensitive time resolution phosphor as a marker and marking the antigenon the fluorescent microspheres and carrying out analysis and detection by means of an immune competitive reaction, the performance of the prepared kit can reach the same chemiluminiscent reagent level. After immune reaction, residual components are fully removed by using a cleaning liquid, and the reading on the fluorescent microspheres bonded to the immune reaction is detected, so that the problem that a developing liquid which is introduced is insufficient in reaction after entering the chip or the reading is not immediate after developing is solved.

A method for removing thyroxine and triiodothyronine from human serum is characterized by comprising steps as follows: adding activated carbon to human serum, performing stirring, and removing activated carbon; then adding kaolin, performing stirring, and removing kaolin. The method for removing thyroxine and triiodothyronine from the human serum has the advantages that the operation is simple, the production cost is low, the removal rate of thyroxine and triiodothyronine is high, and the like.

The medicine has mixed hormone comprising methyl testosterone, testosterone, propiotestosterone and thyroxine, and the mixture is added with algal polysaccharides or alpha-starch and prepared into mediicne stip suitable for embedded into fish body. The medicine of the present invention is embedded into female rockfish's body to induce sexual reversion. Practical test shows that using the mixed external hormone of the medicine can shorten female rockfish's sexual reversion period to 80 days with stable and reliable effect and no sexual restoring.

Methods are provided for inhibiting replication of an RNA virus in a cell infected with the virus, wherein the cell is characterized as having been or concurrently being exposed to a physiologically relevant concentration of a compound selected from ethanol, acetate, isopropanol, acetaldehyde or acetone, comprising contacting the cell with an effective amount of one or more of a HMG-CoA reductase inhibitor, a fatty acid biosynthesis inhibitor, thyroxine, or an agent promoting clearance of the compound from a cell. Also provided are methods to treat a subject having one or more cells characterized as having a physiological concentration of ethanol, acetate, isopropanol, acetaldehyde or acetone, in particular subjects that suffer chronic alcoholics, diabetes or starvation.

The inventive medicinal agent for preventing and treating endocrine system disturbances appears as a powder prepared from ossified reindeer horns and contains 120 IU / g of luteinizing hormone, and 54 IU / g of follicle-stimulating hormone, 2,1 IU / g of prolactin, 203 pg / g of adrenocorticotropic hormone, 2,2 ng of somatotropic hormone, thyroidal hormones including 54 fmol / g of free thyroxin, 8 fmp / g of free triiodothyronine, 4,.5 μU / g of thyreotropic hormone, and 25 pmol / g of cortisol.

The invention belongs to the technical field of immunodiagnosis, and discloses a thyroxine (T4) enzymatic chemiluminescence quantitative determination kit. The kit disclosed by the invention consists of a T4 standard product, an antibody pre-coated reaction plate, a horseradish peroxidase marker, diluent, cleaning mixture, and chemiluminescence substrate liquid. The kit disclosed by the inventionhas the advantages of quickness, handiness, sensitiveness, cheapness and high repeatability, and is an important index for diagnosis and therapeutic evaluation of hyperthyroidism and hypothyroidism. The invention has high clinic use value. The invention also provides a method to prepare the kit.

The invention discloses a method for treating fatty liver by high heat conduction clothing, and a material. In the method, clothing which is made of non-insulated high heat conduction shell fabric is used for accelerating heat of a human body to be released outward through skin of the whole body, promoting metabolism of human cells and tissues, increasing blood flow volume of the skin, removing microcirculation obstacle, eliminating weariness of the human body and making a people energetic, exciting fat in the human body to be converted into heat, and increasing secretion of thyroxine so as to treating fatty liver.